Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2-Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes.

30.67 ± 3.59 kg/m 2 ; p = 0.073); overall, in the group treated with Dapa, the diminution of BMI was highly significant (32.04 ± 4.49 vs. 31.40 ± 4.18 kg/m 2 ; p = 0.006); in patients treated on Empa 10 mg+metformin, the reduction in BMI was significant (34.64 ± 5.80 vs. 33.14 ± 5.70 kg/m 2 ; p = 0.002); in patients treated with Empa 25 mg+metformin, the decrease in BMI was insignificant (33.45 ± 3.82 vs. 33.22 ± 3.84 kg/m 2 ; p = 0.421); overall in the group treated on Empa, the decrease in BMI was significant (34.16 ± 5.08 vs. 33.17 ± 4.99 kg/m 2 ; p = 0.002) ( Figure 4 ).

also in 132,142 other papers